

## Kentucky Medicaid Pharmacy Prior Authorization Form

- For **Drug Requests** (unless noted below) (**DO NOT USE** for Medical benefit or Buy & Bill)— Complete **ONLY** page 1 of **this form**.
- For **ALL Opioid Requests** — Complete page 1, 2,3 **AND** page 4 of **this form**.
- For **Hepatitis C Direct Acting Antiviral (DAA) Therapy** — Complete page 1 **AND** page 5 of **this form**.
- For **Synagis® Requests** — Complete page 1 **AND** page 6 of this form
- For **Buprenorphine Products**:
  - For Pain Management Diagnosis — Complete page 1 **AND** page 2 of **this form**.



Complete each section legibly and completely. Include any supporting documents as needed (lab results, chart notes, etc.).

Plan:	Phone number:	Fax number:
<a href="#">All Kentucky MCO Plans (MedImpact)</a>	1 (844) 336-2676	1 (858) 357-2612

Patient Information:		
Member Name:	Date of Birth:	
Address: City, State, Zip:		
Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female	Height:	Weight:
Member ID:	Medication Allergies:	

Prescriber Information:	
Prescriber Name:	NPI:
Prescriber Address: City, State, Zip:	
Prescriber Specialty:	DEA:
Phone:	Fax:

Diagnosis and Medical Information for Requested Medication:		
<input type="checkbox"/> INITIAL REQUEST <input type="checkbox"/> REAUTHORIZATION (REFILL) Request with current plan		
Diagnosis:	ICD-10 Code:	Date of Diagnosis:
Medication Requested (name, strength and dosage form): <i>If request is for an opioid, please continue to page 2.</i>		
Quantity:	Days' Supply:	Expected Duration of Therapy:
Directions for Use:		

Rationale for Prior Authorization:	
Brand Medically Necessary? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>If yes please answer the following questions:</i>	
1) <i>Has the member tried 2 generic manufacturers</i> <input type="checkbox"/> Yes <input type="checkbox"/> No	
2) <i>Please provide medical justification why the patient cannot be appropriately treated with the generic form of the drug (allergy, intolerance to inactive ingredient)</i> _____	

Request override for Pharmacy Coverage vs Medical? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>If yes please answer the following questions:</i>	
1) Does the physician attest medication is being self-administered AND appropriate per dosage and administration section of the prescriber information? <input type="checkbox"/> Yes <input type="checkbox"/> No	
2) Is the medication being administered by a home infusion provider? <input type="checkbox"/> Yes <input type="checkbox"/> No	
3) Is the medication being used for a compound in compliance with USP 795 standards for non-sterile compounding? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Please indicate previous treatment outcomes below:					
Previous Medication	Strength	Quantity	Directions (Sig)	Dates (from and to)	Reason for Discontinuation

Refer to link for List of Preferred Agents:  
[https://kyportal.magellanmedicaid.com/public/client/static/kentucky/documents/PreferredDrugGuide\\_full.pdf](https://kyportal.magellanmedicaid.com/public/client/static/kentucky/documents/PreferredDrugGuide_full.pdf)  
 Patient recently hospitalized  
*If requesting antibiotics, anti-infective, antidepressants, anticonvulsants, antipsychotic for discharge to complete the course of prescription, provide duration: \_\_\_\_\_ (original + refills)*

Additional Clinical Information or Medical Rationale for Request:

<b>Requesting Provider:</b> <input type="checkbox"/> Prescriber <input type="checkbox"/> Pharmacy *Requestor Name (print):	<b>Date of Request:</b> *Requestor Signature:
---	--

*\*On behalf of the Prescriber or Pharmacy Provider, I certify that the information stated above is true, made to allow Kentucky Medicaid to offer prescription coverage to this member for the medication requested above. I understand the designated health plan will retain this document and any attached materials for the purposes of possible future audit(s).*

**CONTINUE TO PAGE 2 ONLY IF REQUESTING ANY OPIOID**  
**CONTINUE TO PAGE 5 ONLY IF REQUESTING HEPATITIS C DAA THERAPY OR CONTINUE TO PAGE 6 IF REQUESTING SYNAGIS®**

**When requesting ANY OPIOID, provide the following additional information and most recent chart/progress/clinic note:**  
**\*\*For members receiving hospice/palliative/end-of-life care or having a diagnosis of active cancer, this page does not need to be completed.\*\***  
**PLEASE NOTE: ALL OPIOID PA REQUESTS MUST BE COMPLETED BY THE PRESCRIBER ONLY**

**INITIAL TREATMENT REQUESTS ONLY (if request is for continuation therapy skip to question 35)**

Additional Diagnosis (if not stated above):	ICD-10 Code:
---	--------------

1. Prescriber has obtained and reviewed the KASPER report for the past 12 months?  Yes  No
2. Urine drug screen (UDS) has been completed within the past 30 days? **Documentation (e.g., lab result or progress note) required**  
 Yes  No  Not Applicable (member is in a long-term care (LTC) facility or will not exceed 45 days of opioid therapy)
3. Please indicate if the patient has tried or is using any of the following non-opioid therapies:  
 Exercise therapy  
 Cognitive behavioral therapy  
 Nonsteroidal anti-inflammatory drugs (NSAIDs) or Acetaminophen (APAP) Specify: \_\_\_\_\_  
 Other: \_\_\_\_\_
4. Please indicate if the patient has any of the following baseline risk factors:  
 Respiratory depression (clinically significant)  
 Acute or severe bronchial asthma  
 Hypercarbia (clinically significant)  
 Known or suspected GI obstruction  
 If any of the above are true, does the prescriber attest that benefits of opioid use outweigh the risks?  Yes  No
5. Prescriber has assessed baseline pain and function?  Yes (Provide PEG score or documentation of physical exam)  No  
**EXAMPLE: ASSESSING PAIN & FUNCTION USING PEG SCALE**  
**PEG score = average 3 individual question scores**  
**Q1: What number from 0 – 10 best describes your *pain* in the past week?**  
 0 = “no pain”, 10 = “worst you can imagine”    0    1    2    3    4    5    6    7    8    9    10  
**Q2: What number from 0 – 10 describes how, during the past week, pain has interfered with your *enjoyment of life*?**  
 0 = “not at all”, 10 = “complete interference”    0    1    2    3    4    5    6    7    8    9    10  
**Q3: What number from 0 – 10 describes how, during the past week, pain has interfered with your *general activity*?**  
 0 = “not at all”, 10 = “complete interference”    0    1    2    3    4    5    6    7    8    9    10
6. Does the patient meet ONE of the following criteria?  
 a. The patient is receiving hospice, palliative, or end-of-life care  Yes  No  
 b. The patient has a diagnosis of active cancer  Yes  No  
 c. The patient has a diagnosis of sickle cell anemia  Yes  No
7. Does the patient have a diagnosis of severe pain requiring daily, around-the-clock, long-term pain management?  Yes  No  
 If ‘Yes’, proceed to 7a, if ‘No’ proceed to 8  
 a. The patient’s pain lasts: > 3 consecutive months  Yes  No, or > 6 consecutive months  Yes  No  
 b. The patient had a trial and failure within the past 90 days of 1 non-opioid analgesic (i.e., NSAIDs, APAP) at maximum tolerated doses without pain relief and/or functional improvement  Yes  No  
 c. The patient had a trial and failure within the past 90 days of at least 1 short acting opioid analgesic at maximum tolerated doses without adequate relief of pain  Yes  No
8. Does the patient have a diagnosis of diabetic peripheral neuropathy?  Yes  No If ‘Yes’ proceed to 8a, if ‘No’ proceed to 9  
 a. The patient had a trial and failure of ONE serotonin-norepinephrine reuptake inhibitor (SNRI; such as duloxetine)  Yes  No  
 b. The patient had a trial and failure of ONE tricyclic antidepressant (TCA; such as amitriptyline)  Yes  No
9. Does the patient have a diagnosis of neonatal abstinence syndrome (NAS) and meet the following criteria? The patient is being discharged from the hospital on a methadone taper  Yes  No
10. The prescriber has proof of consultation with a pain management specialist  Yes  No OR specialist in an appropriate discipline (e.g., orthopedist, neurologist, spine specialist, etc.) for evaluation of the source of pain and/or treatment of any underlying conditions  Yes  No
11. The patient does NOT have a history of drug or alcohol abuse/dependence or addiction (drug and alcohol toxicology screen results dated within the past month must be submitted with the PA request)  Yes  No
12. The patient is NOT using more than 1 long-acting opioid and 1 short-acting opioid at a time  Yes  No
13. The patient has ONE of the following headache disorders: Muscular headache, Tension-type headache, or Migraine  Yes  No
14. For a high strength (e.g., hydromorphone 8mg) or concentrated dosage form (e.g., morphine sulfate 20 mg/mL, oxycodone 20 mg/mL), please submit a rationale as to why lower strength or less-concentrated products cannot be used \_\_\_\_\_
15. Is the patient opioid naive (defined as ≤ 14 days of opioid use in the past 90 days)?  Yes  No If ‘Yes’, proceed to 15a, if ‘No’ proceed to 16  
 a. The patient is using only 1 short-acting opioid at a time  Yes  No  
 b. Prescribed by a treating physician within 14 days of ONE of the following: major surgery, any operative or invasive procedure or a delivery, significant trauma, being any acute blunt, blast, or penetrating bodily injury that has a risk of death, physical disability, or impairment  
 Yes  No  
 c. If treatment with opioids should extend beyond 14 days please provide clinical justification \_\_\_\_\_
16. Is Long-term (> 3 months) pain management expected or indicated  Yes  No
17. For non-preferred **long acting** opioids: Does the patient have a > 1 month trial and therapeutic failure, allergy, contraindication (including potential drug-drug interactions with other medications) or intolerance to TWO preferred agents  Yes  No, if ‘Yes’ please see question 22.

**Confidentiality Notice:** The information contained in this transmission is confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.

18. For non-preferred **short acting** opioids: The patient had at least a 1-week trial and therapeutic failure, allergy, contraindication (including potential drug-drug interactions with other medications) or intolerance to TWO preferred agents Yes No If 'Yes' please see question 22
19. Does the patient have a diagnosis of cancer pain and meet the following criteria? The patient has been receiving opioid doses greater than or equal to 60 morphine milligram equivalents (MME) per day (e.g., morphine sulfate 60 mg, fentanyl patch 50 mcg/hr, 16 mg hydromorphone, etc.) for at least one week prior to the PA request Yes No
20. If opioid MME exceeding 90 MME per day please provide clinical justification \_\_\_\_\_
21. For opioid MME exceeding 200 MME per day please submit documentation (e.g., progress notes) showing attempts and/or plans to taper below 200 MME/day as well as other non-opioid components (e.g., NSAIDs, physical therapy, etc.) of the treatment plan
22. For tried and failed medications please provide the following information:  
 Medication name, strength, dosage \_\_\_\_\_  
 Specific start date \_\_\_\_\_  
 Specific end date \_\_\_\_\_

**Female Patients of Child-bearing Age Only:**

23. Has the patient been counseled on the risk of becoming pregnant while on this medication and the risk of neonatal abstinence syndrome?  
Yes No

**Naloxone Attestation:**

24. Are any of the following true?
- a. Patient UDS is positive for illicit or unexpected substances Yes **(clinical justification required)** No
- b. Morphine milligram equivalent (MME) is over 90 MME per day Yes **(clinical justification required)** No
- c. Opioid(s) is/are prescribed concurrently with benzodiazepines Yes **(clinical justification required)** No

If yes, prescriber attests that a naloxone prescription and associated counseling on its use, was or will be **given** to the patient: Yes No

25. Are any of the following true?
- a. Opioid(s) is/are concurrently prescribed with a skeletal muscle relaxant Yes No
- b. Opioid(s) is/are concurrently prescribed with a sedative hypnotic Yes No
- c. Opioid(s) is/are concurrently prescribed with gabapentin or pregabalin Yes No
- d. Patient has a history of opioid or other controlled substance overdose Yes No
- e. Patient has a history of substance use disorder (SUD) Yes No

If yes, prescriber attests that a naloxone prescription and associated counseling on its use was, or will be, **offered** to the patient: Yes No

26. For non-preferred agents: Please provide clinical rationale to constitute the use of the requested formulation \_\_\_\_\_

**Requests over 90 or 200 MME per day:**

27. For requests over 90 MME: Prescriber is, or has proof of consultation with, a Pain Management Specialist OR a specialist in an appropriate discipline (e.g., orthopedist, neurologist, spine specialist, etc.) for evaluation of the source of pain and/or treatment of any underlying conditions.  
Yes No
28. For requests over 200 MME: The prescriber is, or has proof of consultation with, a Pain Management Specialist Yes No
29. Clinical justification for exceeding 90 or 200 MME per day \_\_\_\_\_
30. Prescriber attests that a naloxone prescription and associated counseling on its use was or will be offered to the member Yes No
31. For requests over 200 MME: prescriber submitted documentation (e.g., progress notes) showing attempts and/or plans to taper below 200 MME/day as well as other non-opioid components (e.g., NSAIDs, physical therapy, etc.) of the treatment plan

**Concomitant use of Opioids and Benzodiazepines:**

32. Has the member and/or caregiver(s) been counseled about the increased risks of slowed or difficult breathing and/or excessive sedation, and the associated signs and symptoms? Yes No
33. The prescriber attests that a naloxone prescription and associated counseling on its use was or will be given to the member Yes No
34. Clinical justification for the concurrent use of benzodiazepine(s) and opioid(s) \_\_\_\_\_

**REAUTHORIZATION (REFILL) REQUESTS ONLY (with current plan)**

**PLEASE NOTE: ALL OPIOID PA REQUESTS MUST BE COMPLETED BY THE PRESCRIBER ONLY**

- 35. Does the patient meet ONE of the following criteria?
  - a. The patient is receiving hospice, palliative, or end-of-life care  Yes  No
  - b. The patient has a diagnosis of active cancer  Yes  No
  - c. The patient has a diagnosis of sickle cell anemia  Yes  No
- 36. Prescriber has obtained and reviewed the KASPER report within the past 3 months?  Yes  No
- 37. Urine drug screen (UDS) results:  Positive  Negative Date: \_\_\_\_\_
- 38. Prescriber has assessed risk (check box) and documents (e.g., lab result, progress note) a urine drug screen (UDS) within the listed timeframe:
  - Low Risk (12 months)  Moderate Risk (6 Months)  High Risk (3 Months)  Not Applicable (member is in a long-term care facility)
- 39. If patient UDS is positive for illicit or unexpected substances:
  - a. Please provide explanation \_\_\_\_\_
  - b. Will naloxone prescription and counseling be provided  Yes  No
- 40. Prescriber has reassessed pain and function. Provide PEG score \_\_\_\_\_ or clinical documentation (e.g., progress note): \_\_\_\_\_
- 41. The patient has demonstrated a 30% improvement from baseline to continue current dose  Yes  No  
OR includes the rationale for continued opioid therapy at the current dose \_\_\_\_\_
- 42. Has the patient required use of opioid rescue medication (e.g., naloxone), been hospitalized, or otherwise treated for opioid or other controlled substance overdose in the past 6 months?  Yes *If 'Yes' please provide plan for preventing future overdose*  No

**Female Patients of Child-bearing Age Only:**

- 43. Does the PRESCRIBER attest that the patient has been counseled on the risk of becoming pregnant while on this medication and the risk of neonatal abstinence syndrome?  Yes  No

**Requests over 90 or 200 MME per day:**

- 44. For requests over 90 MME: Prescriber is, or has proof of consultation with, a Pain Management Specialist OR a specialist in an appropriate discipline (e.g., orthopedist, neurologist, spine specialist, etc.) for evaluation of the source of pain and/or treatment of any underlying conditions.  Yes  No
- 45. For requests over 200 MME: The prescriber is, or has proof of consultation with, a Pain Management Specialist  Yes  No
- 46. Clinical justification for exceeding 90 or 200 MME per day \_\_\_\_\_
- 47. Prescriber attests that a naloxone prescription and associated counseling on its use was or will be offered to the member  Yes  No
- 48. For requests over 200 MME: prescriber submitted documentation (e.g., progress notes) showing attempts and/or plans to taper below 200 MME/day as well as other non-opioid components (e.g., NSAIDs, physical therapy, etc.) of the treatment plan

**Concomitant use of Opioids and Benzodiazepines:**

- 49. Does the PRESCRIBER attest that the member and/or caregiver(s) been counseled about the increased risks of slowed or difficult breathing and/or excessive sedation, and the associated signs and symptoms?  Yes  No
- 50. The prescriber attests that a naloxone prescription and associated counseling on its use was or will be given to the member  Yes  No
- 51. Clinical justification for the concurrent use of benzodiazepine(s) and opioid(s) \_\_\_\_\_

Additional Clinical Information or Medical Rationale for Request (please attach additional pages/documentation as needed):

**CONTINUE TO PAGE 5 ONLY IF REQUESTING HEPATITIS C DAA THERAPY OR CONTINUE TO PAGE 6 IF REQUESTING SYNAGIS®**

When requesting **Hepatitis C Direct-Acting Antiviral (DAA) Therapy**, provide the following additional information:

<b>Diagnosis Criteria and Simplified Treatment Eligibility</b>	Date of Hepatitis C diagnosis (or earliest record):	<p><b>Female Patients of Child-bearing Age Only:</b></p> <p>Is the patient pregnant or nursing? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, Prescriber attests that the benefits of HCV treatment outweigh potential risks <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
	<ol style="list-style-type: none"> <li>1. Quantitative HCV RNA level (HCV viral load) (must be within 3 months) Date: _____ Result: _____</li> <li>2. Which of the following applies to this patient?               <ol style="list-style-type: none"> <li>a. Previously treated for Hepatitis C? If so, provide details below. <input type="checkbox"/> Yes <input type="checkbox"/> No (treatment-naïve)</li> <li>b. Cirrhosis (FIB-4 score &gt; 3.25 or other clinical indicators)? <input type="checkbox"/> Yes <input type="checkbox"/> No cirrhosis (FIB-4 score &lt; 3.25)                   <ul style="list-style-type: none"> <li>• If 'No', FIB-4 score (<a href="https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4">https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4</a>) is: _____</li> <li>• If 'Yes', is it <input type="checkbox"/> compensated (Child Pugh A) or <input type="checkbox"/> decompensated (Child Pugh B or C) cirrhosis?</li> </ul> </li> <li>c. Human immunodeficiency virus (HIV) positive? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>d. Hepatitis B surface antigen (HBsAg) positive? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>e. History of liver transplant? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>f. Known or suspected hepatocellular carcinoma (HCC)? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> </ol> </li> <li>3. If 'No' to all of the above, the patient is eligible for simplified treatment; stop here. If 'Yes', proceed to question 4.</li> <li>4. If 'Yes' to any of the items above, the patient is NOT eligible for simplified treatment; please provide the following:               <ol style="list-style-type: none"> <li>a. HCV genotype: _____ subtype _____ resistance mutations _____</li> <li>b. Prior HCV treatment experience (medication/dates; if applicable): _____</li> </ol> </li> <li>5. Prescriber qualification/specialty: <input type="checkbox"/> HCV academic/mentorship program or network (e.g., KHAMP, ECHO) <input type="checkbox"/> Gastroenterology <input type="checkbox"/> Hepatology <input type="checkbox"/> Infectious Disease <input type="checkbox"/> HIV Specialist (AAHIVS) <input type="checkbox"/> Transplant</li> <li>6. Is the prescribed treatment regimen included in the requested drug's package insert and/or supported by current HCV guidelines for the patient's age/weight <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>7. For nonpreferred drugs: is there clinical justification (e.g., allergy, contraindication, potential drug-drug interactions with other medications, or intolerance) as to why preferred drugs cannot be used or are not indicated: _____</li> <li>8. Was the patient previously treated with a direct-acting antiviral? <input type="checkbox"/> Yes <input type="checkbox"/> No If 'No'; stop here. If 'Yes', proceed to Repeat DAA Therapy Questions.</li> </ol>	
<b>Repeat DAA Therapy Questions</b>  (complete only if requesting repeated DAA therapy)	<ol style="list-style-type: none"> <li>1. Is retreatment necessary due to treatment failure or reinfection? <input type="checkbox"/> Treatment Failure <input type="checkbox"/> Reinfection</li> <li>2. Was the patient compliant with previous DAA therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No (if no justification must be provided: _____)</li> <li>3. Were there any additional factors that led to DAA treatment failure? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>If yes, how have these been addressed?</i> _____</li> <li>4. Does the patient have a recent history of alcohol or substance abuse? <input type="checkbox"/> Yes (proceed to 4a) <input type="checkbox"/> No (proceed to 5)               <ol style="list-style-type: none"> <li>a. Patient has completed/is participating in a recovery program, receiving alcohol or substance abuse counseling services, or seeing an addiction specialist as part of HCV treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>b. Patient has been evaluated for alcohol and substance abuse using a validated screening tool <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>c. Patient is not actively participating in illicit substance use or alcohol abuse with confirmatory laboratory testing (e.g., urine drug screen) <input type="checkbox"/> Yes <input type="checkbox"/> No</li> </ol> </li> <li>5. Patient is willing and able to comply with requirements of the retreatment plan? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>6. Patient has been educated regarding risk behaviors associated with HCV infection? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>7. The prescriber has addressed any factors that may have led to noncompliance with previous treatment(s) <input type="checkbox"/> Yes <input type="checkbox"/> No</li> </ol>	

**When requesting Synagis<sup>®</sup>, provide the following additional information:**

Note: For the 2022-2023 season, therapy may begin October 1, 2022 with last date of therapy no later than March 31, 2023 (end of RSV season).

Synagis is available in 50mg and 100mg vials. Always coordinate dosing appropriately to reduce waste.

1. Patient's gestational age at birth: \_\_\_\_\_ weeks \_\_\_\_\_ days
2. Does the patient have Chronic Lung Disease of Prematurity (formerly called bronchopulmonary dysplasia)?
  - Yes (proceed to 2a)     No (proceed to 3)
  - a. Did the patient receive oxygen immediately following birth?     Yes (proceed to 2b)     No (proceed to 3)
  - b. Please indicate the % oxygen received: \_\_\_\_\_ Date received: \_\_\_\_\_ Duration of treatment: \_\_\_\_\_
  - c. Does the patient require medical support (chronic systemic steroids, diuretic therapy, or supplemental oxygen) within 6 months before the start of the second RSV season?     Yes     No
3. Does the patient have a diagnosis of Cystic Fibrosis?     Yes (proceed to 3a)     No (proceed to 4)
  - a. Has the patient been hospitalized for a pulmonary exacerbation?     Yes (Date: \_\_\_\_\_)     No
  - b. Does the patient have clinical evidence of chronic lung disease and/or nutritional compromise?     Yes     No
  - c. Does the patient have clinical evidence of failure to thrive?     Yes     No
  - d. Does the patient have pulmonary abnormalities on chest X-ray or CT that persist when the patient is stable?     Yes     No
  - e. What is the patient's weight for length percentile? \_\_\_\_\_
4. Please indicate if the patient has any of the following:
  - Anatomic Pulmonary Abnormality    Specify: \_\_\_\_\_
  - Neuromuscular Disorder    Specify: \_\_\_\_\_
  - Congenital anomaly that impairs the ability to clear secretions    Specify: \_\_\_\_\_
5. Please indicate if the patient has any of the following:
  - HIV
  - Cancer, receiving chemotherapy
  - Organ transplant receiving immunosuppressant therapy or hematopoietic stem cell transplant
  - Other medical condition that is severely immunocompromising.    Specify: \_\_\_\_\_
6. Has this patient received a heart transplant?     Yes (Date: \_\_\_\_\_)     No
7. Does patient have hemodynamically significant congenital heart disease?     Yes     No
  - Acyanotic heart disease    Specify: \_\_\_\_\_
  - Cyanotic heart disease    Specify: \_\_\_\_\_    Name of Pediatric Cardiologist: \_\_\_\_\_
  - Pulmonary Hypertension
  - Other: \_\_\_\_\_
8. Will this patient's congenital heart disease require cardiac surgery?     Yes     No
9. Please list any pharmaceutical therapies for cardiovascular disease and the most recent date administered:
 

Cardiovascular medication(s): \_\_\_\_\_ Most recent date administered: \_\_\_\_\_
10. If this is a request for a sixth dose of Synagis<sup>®</sup> during the RSV season, has the patient had an ECMO or cardiac bypass during the RSV season?
  - Yes (Date: \_\_\_\_\_)     No